Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals Inc. (GB:0LKB)
LSE:0LKB
Holding GB:0LKB?
Track your performance easily
0LKB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.30 - $6.75
Previous Close$4.92
Volume14.71K
Average Volume (3M)1.80K
Market Cap
$288.53M
Enterprise Value-$93.14M
Total Cash (Recent Filing)$387.68M
Total Debt (Recent Filing)$6.00M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Oct 30, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,289,808
10 Day Avg. Volume1,449
30 Day Avg. Volume1,800
Standard Deviation0.13
R-Squared0.06
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.53
Price to Sales (P/S)1.59
Price to Cash Flow (P/CF)-10.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.51
Enterprise Value/Gross Profit-0.52
Enterprise Value/Ebitda7.84
Forecast
1Y Price Target
$13.00Price Target Upside180.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Vanda News
Options Prices
Currently, No data available
---
Ownership Overview
29.26% Insiders
22.53% Mutual Funds
31.76% Other Institutional Investors
16.45% Public Companies and
Individual Investors
0LKB FAQ
What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Vanda Pharmaceuticals Inc. lowest share price was $3.29 and its highest was $6.75 in the past 12 months.
What is Vanda Pharmaceuticals Inc.’s market cap?
Currently, no data Available
When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
Vanda Pharmaceuticals Inc.’s upcoming earnings report date is Oct 30, 2024 which is in 40 days.
How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
Vanda Pharmaceuticals Inc. released its earnings results on Jul 31, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.11.
Is Vanda Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vanda Pharmaceuticals Inc. pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
What is Vanda Pharmaceuticals Inc.’s EPS estimate?
Vanda Pharmaceuticals Inc.’s EPS estimate is -$0.16.
How many shares outstanding does Vanda Pharmaceuticals Inc. have?
Vanda Pharmaceuticals Inc. has 58,289,806 shares outstanding.
What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
Vanda Pharmaceuticals Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -4.696%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
Among the largest hedge funds holding Vanda Pharmaceuticals Inc.’s share is Graham Capital Management, L.P.. It holds Vanda Pharmaceuticals Inc.’s shares valued at N/A.
---
Vanda Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (180.72% Upside)
$13.00 (180.72% Upside)
Blogger Sentiment
Bullish
GB:0LKB Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $13.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.98%
12-Months-Change
Fundamentals
Return on Equity
-2.02%
Trailing 12-Months
Asset Growth
1.51%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
---
0LKB Earnings Call
Q2 2024
0:00 / 0:00
---
0LKB Stock 12 Month Forecast
Average Price Target
$13.00
▲(180.72% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Eagle Pharmaceuticals
―
Supernus Pharmaceuticals
―
Avadel Pharmaceuticals
―
Vanda
―
Best Analysts Covering 0LKB
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-14.00%
reiterated a buy rating 2 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -14.00% per trade.
---